Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
F2RL2 Biologics Sequence Review Report 2026: Proteinase-activated receptor 3 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
F2RL2 Biologics Sequence Review Report 2026: Proteinase-activated receptor 3 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of F2RL2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
GRM8 Biologics Sequence Review Report 2026: Metabotropic glutamate receptor 8 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
GRM8 Biologics Sequence Review Report 2026: Metabotropic glutamate receptor 8 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of GRM8 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
AIP Biologics Sequence Review Report 2026: AH receptor-interacting protein Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
AIP Biologics Sequence Review Report 2026: AH receptor-interacting protein Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of AIP protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CD5 Biologics Sequence Review Report 2026: T-cell surface glycoprotein CD5 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CD5 Biologics Sequence Review Report 2026: T-cell surface glycoprotein CD5 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of CD5 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CD8A Biologics Sequence Review Report 2026: T-cell surface glycoprotein CD8 alpha chain Similarity and Patent-Risk Signals
8 min read
CD8A Biologics Sequence Review Report 2026: T-cell surface glycoprotein CD8 alpha chain Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of CD8A protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
TNFRSF17 Biologics Sequence Review Report 2026: Tumor necrosis factor receptor superfamily member 17 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
TNFRSF17 Biologics Sequence Review Report 2026: Tumor necrosis factor receptor superfamily member 17 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of TNFRSF17 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CD79B Biologics Sequence Review Report 2026: B-cell antigen receptor complex-associated protein beta chain Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CD79B Biologics Sequence Review Report 2026: B-cell antigen receptor complex-associated protein beta chain Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of CD79B protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
FCGR2C Biologics Sequence Review Report 2026: Low affinity immunoglobulin gamma Fc region receptor II-c Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
FCGR2C Biologics Sequence Review Report 2026: Low affinity immunoglobulin gamma Fc region receptor II-c Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of FCGR2C protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
FCGR2B Biologics Sequence Review Report 2026: Low affinity immunoglobulin gamma Fc region receptor II-b Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
FCGR2B Biologics Sequence Review Report 2026: Low affinity immunoglobulin gamma Fc region receptor II-b Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of FCGR2B protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CD247 Biologics Sequence Review Report 2026: T-cell surface glycoprotein CD3 zeta chain Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CD247 Biologics Sequence Review Report 2026: T-cell surface glycoprotein CD3 zeta chain Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of CD247 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
GPR50 Biologics Sequence Review Report 2026: Melatonin-related receptor Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
GPR50 Biologics Sequence Review Report 2026: Melatonin-related receptor Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of GPR50 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
KLRD1 Biologics Sequence Review Report 2026: Natural killer cells antigen CD94 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
KLRD1 Biologics Sequence Review Report 2026: Natural killer cells antigen CD94 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of KLRD1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →